Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4 Description of Capital Stock
- 10.17 Assignment and Assumption Agreement Between Allarity Therapeutics, Inc. and Allarity A/s
- 10.18 Exclusive License Agreement with Oncoheroes Bioscience, Inc. Dated January 2, 2022 (Stenoparib)
- 10.19 Exclusive License Agreement with Oncoheroes Bioscience, Inc. Dated January 2, 2022 (Dovitnib)
- 10.20 Amended and Restated License Agreement Among Allarity Therapeutics Europe Aps, Liplasome Pharma Aps, and Chosa Aps Dated March 28, 2022
- 10.21 Support Agreement Between Allarity Therapeutics A/s and Liplasome Pharma Aps, Dated March 28, 2022
- 21.1 Subsidiaries of the Registrant
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
ALLR similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Allarity Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, in the capacities and on the date indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. |
Date: May 16, 2022
By: | /s/ Jens Erik Knudsen | |
Name: | Jens Erik Knudsen | |
Title: | Chief Financial Officer | |
(Principal Financial Officer) |